Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Total Liabilities (2018 - 2026)

TransMedics has reported Total Liabilities over the past 8 years, most recently at $595.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 3.44% year-over-year to $595.3 million; the TTM value through Dec 2025 reached $595.3 million, up 3.44%, while the annual FY2025 figure was $595.3 million, 3.44% up from the prior year.
  • Total Liabilities for Q4 2025 was $595.3 million at TransMedics, up from $590.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $595.3 million in Q4 2025 and troughed at $48.1 million in Q1 2021.
  • A 5-year average of $345.6 million and a median of $554.0 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: decreased 4.24% in 2021 and later soared 721.42% in 2023.
  • Year by year, Total Liabilities stood at $67.0 million in 2021, then surged by 33.91% to $89.8 million in 2022, then surged by 533.66% to $568.8 million in 2023, then rose by 1.17% to $575.5 million in 2024, then rose by 3.44% to $595.3 million in 2025.
  • Business Quant data shows Total Liabilities for TMDX at $595.3 million in Q4 2025, $590.8 million in Q3 2025, and $572.4 million in Q2 2025.